Lead Product(s) : Methsuximide
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ANI Pharmaceuticals Announces FDA Approval and Commercialization of Two ANDAs with CGT Exclusivity
Details : Methsuximide elevates the seizure threshold and reduces the frequency of attacks through depression of nerve transmission in the cortex.
Product Name : Celontin-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 15, 2023
Lead Product(s) : Methsuximide
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
